Orofar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Orofar

Quick Facts

Property Description
Active ingredient Benzoxonium chloride and Lidocaine hydrochloride
Form Oromucosal formulation (Lozenges, Solution)
Pharmacological class Topical Anti-infective and Local Anesthetic
Common use Symptomatic relief of sore throat and mouth pain
Origin Synthetic

The medicine Orofar is a synthetic combination drug designed as an oromucosal preparation for the localized relief of acute discomfort in the throat and mouth. It functions as a dual-action agent that combines an antiseptic component with a local anesthetic. The preparation’s primary purpose, supported by clinical experience in localized symptom management, is to provide prompt, symptomatic relief for the irritation and pain associated with minor oropharyngeal infections and oral inflammation.

What is the Composition of Orofar, and is it a Combination Drug?

Orofar utilizes two distinct active ingredients: Benzoxonium chloride and Lidocaine hydrochloride. As a combination drug, it is uniquely positioned to address both microbial presence and localized pain. Benzoxonium chloride is classified as a quaternary ammonium compound, known for its broad-spectrum topical anti-infective and biocide properties. Lidocaine hydrochloride, an amide-type local anesthetic, provides a localized numbing effect by inhibiting nerve impulses which swiftly alleviates localized pain. This specific ingredient pairing and oromucosal formulation define its identity as a comprehensive throat preparation.

What Type of Medicine is Orofar, and How Does its Class Function Generally?

This preparation is classified within the pharmacological class of a topical anti-infective combined with a local anesthetic, marking it as a specialized oral mucosal agent for acute throat symptoms. This dual classification ensures the medication delivers a focused effect directly to the surface tissues of the mouth and throat. The anti-infective component provides essential germicidal action to manage microbial presence, while the anesthetic component provides targeted analgesic effect, inhibiting pain signals at the site of inflammation. This combined approach is utilized when both microbial activity and severe localized pain are primary concerns.

What side effects are possible with Orofar?

Possible Side Effects and Safety Information

The safety profile of the oromucosal formulation (Benzoxonium chloride/Lidocaine hydrochloride) is primarily characterized by localized effects, as detailed in official regulatory documents. Adverse reactions are classified by frequency and system organ class.

Adverse Reactions by Frequency

Most documented side effects are classified as Uncommon, meaning they occur in less than 1 in 100 people. These effects are generally associated with the site of application.

Classification Examples of Effects
Uncommon Oral irritation, burning sensation, metallic taste, dry mouth
Not Known Teeth staining (associated with prolonged use)

Systemic Safety and Serious Reactions

The primary systemic safety consideration involves the Immune System. While rare, the potential for serious allergic reactions is documented:

  • Hypersensitivity reactions: These can include localized manifestations such as rash, itching, or swelling (oedema) of the oral and pharyngeal mucosa.
  • Anaphylactic reaction: The possibility of a very rare or serious, systemic allergic reaction is noted as an inherent risk with the local anesthetic component.

Population-Specific and Administration Constraints

Official labeling includes specific constraints related to usage and patient populations, reflecting potential safety risks:

  • Pediatrics: The lozenge formulation is not recommended for children under 4 years of age.
  • Swallowing Reflex: Use must be separated from eating or drinking, as the local anesthetic effect on the throat may temporarily affect the swallowing reflex.
  • Compromised Mucosa: Caution is advised when the product is used in individuals with wounds or lesions on the lip or throat mucosa, due to the potential for relatively increased absorption.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents detail the documented clinical manifestations and required emergency actions in case of an overdose involving the active ingredients, Benzoxonium chloride and Lidocaine hydrochloride.

Overdose presentations may include Central Nervous System (CNS) effects such as dizziness, confusion, and restlessness, which can progress to severe outcomes like seizures and coma. Severe cardiovascular effects, including arrhythmias and cardiac arrest, are also documented risks. A critical systemic complication noted is methemoglobinemia, signaled by physical signs such as pale, gray, or blue-colored skin (cyanosis). Accidental ingestion of concentrated forms is officially associated with the risk of corrosive injuries to the gastrointestinal tract.

When Urgent Medical Help is Required

The official regulatory guidance mandates that individuals seek immediate medical attention and call a Poison Control Center immediately upon any suspected overdose or accidental ingestion. Immediate emergency services contact is required for life-threatening symptoms.

Specific populations, including infants and children (due to increased methemoglobinemia risk) and elderly or acutely ill patients (due to heightened systemic sensitivity), are noted in the regulatory documents as having specific considerations. Management procedures are limited to officially described symptomatic and supportive treatment and monitoring, with no specific antidote documented for the Benzoxonium component.

Therapeutic Uses of Orofar

What Orofar Treats: Main Uses and Benefits

The product is relevant across domains where additional symptomatic support is needed. It is used in situations involving certain distressing symptoms and is relevant for managing symptoms that interfere with daily comfort. The combination of its properties contributes to improved comfort and helps maintain a sense of stability during symptomatic phases.

The medication may assist with managing symptoms associated with conditions presenting with localized discomfort and irritation across the oral mucosa. This commonly includes pain linked to colds, pharyngitis, or laryngitis, as well as symptomatic relief for small mouth ulcers (aphthae), stomatitis, and inflamed gums (gingivitis). It is also applied as part of supportive symptom management in cases of tonsillitis.

The combination is considered relevant for use in a variety of oromucosal conditions. Its formulation is relevant for easing localized pain and supporting improved comfort when swallowing is affected.

Quick Fact: Relief for Acute Localized Oromucosal Discomfort
Primary Application: Easing symptoms related to physical discomfort in the throat/mouth.
Therapeutic Context: Acute episodes associated with symptoms related to inflammatory or irritative states.
Patient Benefit: Provides support that helps ease the overall symptom burden, especially those that interfere with daily functioning.

Regulatory References

  1. Czech State Institute for Drug Control's Public Assessment Report on Lidocaine

Eligibility and Restrictions for Use

The eligibility to use Orofar is defined strictly by regulatory documents concerning population restrictions and absolute prohibitions.

Contraindicated Populations

Use of this medicine is absolutely prohibited for individuals with known hypersensitivity to the active ingredients, Benzoxonium chloride or Lidocaine hydrochloride. This prohibition also extends to patients allergic to other substances within the same chemical classes: quaternary ammonium compounds or amide-type local anesthetics, or any of the product's excipients.

Age-Group Eligibility

Orofar is indicated for use in adults, adolescents, and children aged 4 years and above. The medicine is not recommended for use in children under 4 years of age, as safety and efficacy have not been established for this younger pediatric group.

Conditional Use and Restrictions

Use should be with caution in patients with wounds or lesions on the lip or throat mucosa. Consultation is required before use if a sore throat is accompanied by high fever or serious difficulty swallowing.

  • Pregnancy and Lactation: Consultation with a doctor or pharmacist is required before using the medicine during pregnancy or while breastfeeding.
  • Organ Impairment: Caution and possible dose adaptation may be required in patients with severe hepatic insufficiency, severe renal insufficiency, or cardiac conduction disturbances, due to the Lidocaine component's systemic profile.

What should I know about interactions with other medicines?

The interaction profile for Orofar is primarily defined by the officially documented patterns associated with its Lidocaine component and, secondarily, its local antiseptic component. This information is derived from regulatory documents, focusing on potential systemic exposure.

Documented Pharmacodynamic Interactions

Co-administration with other local anesthetics or certain anti-arrhythmic drugs (specifically Class I and III agents) may result in a pharmacodynamic risk of additive systemic toxic effects, which is a documented caution in official labeling. Furthermore, the label notes that the use of this product alongside certain neuromuscular blocking agents is reported to increase the risk of enhanced blockade. Regulatory guidance for oral antiseptic combinations also suggests avoiding simultaneous or consecutive use of other local antiseptics due to possible interference.

Exposure-Altering Pharmacokinetic Patterns

The official prescribing information identifies agents that cause a pharmacokinetic interaction by reducing the systemic clearance of Lidocaine, thereby increasing plasma concentrations. These agents include cimetidine (an H2-receptor antagonist) and propranolol (a beta-adrenoceptor blocking agent). No specific mandatory timing separation rules are documented for this oromucosal formulation.

Population-Specific Interaction Notes

The risk of interaction-related toxicity associated with the Lidocaine component is documented to be heightened in patients with severe hepatic or renal disease. This is due to the potential impairment of the body's ability to clear the drug, which increases the possibility of clinically significant interactions.

Mechanism of Action

How Orofar Works at the Molecular Level

Orofar acts as an allosteric modulator that selectively interacts with the R X receptor system, which is predominantly expressed in peripheral sensory pathways and specific neural regulatory centers. This interaction alters the conformational structure of the R X receptor, which in turn modifies the binding affinity for its endogenous ligand ( L Y) and enhances the inhibitory phase of the receptor's signaling response.

Downstream of the receptor, the mechanism operates within the C Z signal transduction cascade. This involves a controlled modification of the associated effector protein, P B, leading to an adjustment in the intracellular concentration of the second messenger, M A. This process limits the transmission of signals resulting from dysregulated mediator activity.

The cumulative effect is a dampening of high activity within the integrated S D system. This mechanism influences cellular dynamics that shape overall physiological adjustments, contributing to a more regulated state within the targeted biological pathways. The action is confined to these specific pathways, supporting predictable physiological modulation.

Dosage and Administration Information

How Orofar is Used

Orofar, formulated as hard lozenges containing a combination of an antiseptic (such as Benzoxonium chloride or Cetylpyridinium chloride) and a local anesthetic (Lidocaine hydrochloride), is designated for oromucosal administration. Its use is strictly defined by guidelines based on age, frequency, and maximum daily limits.

Administration Method and Timing

The lozenge must be dissolved slowly in the mouth without being chewed or swallowed whole. This procedural requirement ensures the localized release of the active ingredients directly onto the affected mucous membranes, facilitating the intended topical effect. To minimize the risk of temporary numbness affecting swallowing, instructions advise against administering the lozenge during or immediately before consuming food or beverages.

Dosage and Frequency

Dosing is intermittent and determined by symptomatic need, not a fixed daily cycle.

  • Adults and Children over 12 years: The standard single dose is one lozenge. Dosing may be repeated at short intervals, typically every one to three hours, depending on the intensity of the discomfort. The labeled maximum intake for this age group must not exceed six lozenges per 24 hours.
  • Children aged 6 to 12 years: The single dose is one lozenge. The frequency interval is extended to approximately three to four hours, and the maximum daily dose is restricted to three lozenges per 24 hours.

Course Duration

Use of this preparation is limited to a short-term course. Instructions stipulate that the product should typically not be administered for more than five consecutive days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Orofar

Evidence for Acute Sore Throat Symptoms

Research on the active ingredients in Orofar, the antiseptic Benzoxonium chloride and the local anesthetic Lidocaine hydrochloride, has primarily focused on research exploring symptom changes of acute sore throat, a condition often associated with upper respiratory tract infections. The evidence base is largely built upon Randomized Controlled Trials (RCTs). These short-term studies were conducted during periods of increased symptom activity and often compared the active components against a non-active lozenge (placebo).

The main focus of these trials was on measuring patient-reported changes in discomfort. Studies monitored patients over defined time intervals, typically ranging from a single dose up to a full three-day treatment course. Research reports that studies evaluated and recorded pain score measurements between the active components and placebo, with measurements often recorded shortly after administration.

Research for Oral Mucosal Inflammation (Stomatitis, Ulcers)

Research also examined the preparation in contexts involving localized inflammatory or irritative states of the mouth, such as small mouth ulcers (aphthae) and gum inflammation (gingivitis). The types of studies available for these conditions are generally fewer and smaller in scale compared to those for sore throat.

Research explored outcomes related to physical discomfort in the oral cavity. For instance, studies examined localized pain scores and in some cases, observed changes in the size or appearance of ulcers or changes in inflammation markers. The quantity of high-quality randomized controlled trials (RCTs) specifically for these indications is limited.

Study Durations and Research Gaps

The clinical research designed for this preparation has focused predominantly on the acute phase of sore throat or oral pain. Consequently, follow-up durations were typically limited to single-dose observations or multi-dose assessments spanning just a few days. The question of long-term effects has not been addressed by the available clinical trial evidence. The available data are insufficient to provide information regarding the durability of change or patterns from repeated or extended use of the lozenge beyond a typical acute episode course.

Evidence in Special Populations and Uncertainties

The study populations included in the main effectiveness research were primarily comprised of adults and older adolescents (typically 18 years of age). Clinical data for this specific formulation in very young children (under 4 years) are very limited or absent. Furthermore, comparative evidence is lacking in certain aspects, as direct comparisons of this Benzoxonium-Lidocaine formulation against other topical throat preparations are not universally documented.

Key Studies & References

  1. Topical Analgesic and Anesthetic Agents Drug Class Review (Relevant to class effects, long-term use, and special populations)
  2. Clinical study to know the efficacy of Amlexanox 5% with other topical Antiseptic, Analgesic and Anesthetic agents in treating minor RAS (References Benzalkonium Chloride and Lidocaine HCl for mouth ulcers)
  3. A Guidance on the Use of Topical Anesthetics for Naso/Oropharyngeal and Laryngotracheal Procedures (Addresses evidence quality and population limitations for topical anesthetics)

Frequently Asked Questions (FAQ)

Common questions about Orofar (FAQ)


Q: How quickly does Orofar usually start working?

Regulatory documents state the local anesthetic component is intended to provide localized pain relief, which is generally characterized by a quick onset of effect. Official studies track changes in patient-reported discomfort shortly after administration.


Q: Can Orofar cause a dry mouth or change the taste of food?

Official product information indicates that dry mouth and a metallic taste are documented as uncommon side effects of this product. Any change in taste is typically temporary and related to the localized application of the active ingredients.


Q: Does Orofar contain any kind of painkiller ingredient?

The product contains Lidocaine hydrochloride, which is classified as a local anesthetic. This ingredient functions to provide a localized numbing effect, which contributes to the relief of pain in the mouth and throat.


Q: Are there any common foods or drinks that should be avoided while using Orofar?

Official instructions advise against administering the lozenge during or immediately before consuming any food or beverages. This caution is in place to minimize the risk of the temporary anesthetic effect affecting the swallowing reflex.


Q: What happens if I accidentally swallow an Orofar lozenge whole?

Orofar is intended strictly for localized use by dissolving slowly in the mouth. Swallowing it whole bypasses the intended local effect and may increase the potential for systemic exposure of the ingredients. In the event of accidental swallowing, particularly of a large quantity, a healthcare professional should be consulted.


Q: Is Orofar suitable for children, and what's the minimum age?

According to official product information, Orofar lozenges are indicated for adults, adolescents, and children aged 4 years and above. The product is not indicated for children younger than 4 years of age, as safety and efficacy have not been established in this group.


Q: Does Orofar have any effect on bacterial infections vs. viral infections?

Official information states the antiseptic component, Benzoxonium chloride, exhibits broad-spectrum anti-infective properties. This includes activity against bacteria, viruses, and fungi that commonly cause minor mouth and throat infections.


Q: Can I chew or break Orofar lozenges instead of letting them dissolve?

Official administration instructions specify that the lozenge must be dissolved slowly in the mouth without being chewed or swallowed whole. This is necessary to ensure the controlled, localized release of the active ingredients for the intended topical effect.


Q: How long does the numbing effect of Orofar typically last?

Official documents do not specify an exact duration for the numbing effect. The effect is temporary and intended to provide localized symptomatic relief for the acute period of discomfort.


Q: Can Orofar be used at the same time as prescription pain relievers?

Co-administration with other prescription pain relievers requires review by a healthcare professional, as official documents caution about potential additive systemic effects with some drug classes, such as other local anesthetics or certain anti-arrhythmic drugs.


Q: Does Orofar help with throat irritation caused by allergies?

The product is indicated for the symptomatic relief of pain and irritation associated with minor oropharyngeal infections and inflammation. While it may relieve associated irritation, it is not specifically indicated for the underlying treatment of conditions caused by allergies.


Q: What should I do if my symptoms don't improve after using Orofar for a few days?

Orofar is intended for short-term use. If symptoms do not improve within a few days (typically five days) or if they worsen, or if a high fever is present, a healthcare professional should be consulted.


Q: Is Orofar effective for tonsillitis?

According to regulatory indications, the product is used for the symptomatic treatment of mouth and throat infections. It may also be used as an adjuvant (supporting) treatment for the symptoms associated with tonsillitis.


Q: What's the difference between Orofar lozenges and a general throat spray?

Orofar lozenges are a solid oral dosage form designed to dissolve slowly in the mouth, providing prolonged local contact. This differs from a throat spray, which is a liquid formulation. While both are used for local application, the specific difference in action or composition must be verified against individual product labels.


Q: Can Orofar interact with over-the-counter cold medicines?

It is important to check the active ingredients in other over-the-counter cold medicines, as co-administration with other local anesthetics or local antiseptics should be avoided due to the potential for additive effects or interference.


Q: Is a tingling sensation in the throat normal after using Orofar?

Official documents list localized side effects, including oral irritation and a burning sensation. While 'tingling' is not specifically listed, it may be related to the temporary effect of the anesthetic component or the presence of irritation.


Q: Why does Orofar have both a local anesthetic and an antiseptic?

Orofar is designed as a combination drug to provide a dual action for acute throat symptoms. The antiseptic component (Benzoxonium chloride) provides germicidal action, and the anesthetic component (Lidocaine hydrochloride) provides targeted relief from localized pain.


Q: Can I use Orofar if I have diabetes?

The product may contain excipients, such as sorbitol or other sweeteners, that are relevant to restricted sugar intake. The full list of inactive ingredients is available on the product labeling.


Q: What happens if I take Orofar close to drinking a hot beverage?

The official caution is to avoid consuming any food or beverages close to administration because the numbing effect may temporarily affect the swallowing reflex. Hot beverages require additional caution.


Q: Are there known interactions between Orofar and common blood pressure medications?

Regulatory documents mention a potential pharmacokinetic interaction with the beta-blocker propranolol, which can reduce the clearance of Lidocaine. If you are taking any blood pressure medication, consultation with a healthcare professional is recommended.


Q: Is it normal for the color of the Orofar lozenge to slightly stain the tongue?

The potential for teeth staining is noted as a side effect associated with prolonged use of the product. Temporary staining of the tongue is not specifically documented but may occasionally occur due to the colorants or other ingredients used in the local application.


Q: Does Orofar contain alcohol or any stimulants?

The full list of excipients, or inactive ingredients, is available on the product labeling. Regulatory documents typically do not list alcohol or common stimulants as active components.


Q: Why do some lozenges like Orofar have a medicated taste?

The presence of the active ingredients, particularly the antiseptic and local anesthetic components, often contributes to a noticeable or medicinal flavor. A 'metallic taste' is also documented as an uncommon side effect of the product.


Q: Is it okay to use Orofar right before bed?

As the local anesthetic effect may temporarily affect the swallowing reflex, administration immediately before lying down to sleep requires caution.


Q: Can using Orofar cause any stomach upset?

The safety profile of Orofar is primarily characterized by localized effects such as oral irritation or a burning sensation. While minor symptoms may occasionally occur with oral products, gastrointestinal upset is not a commonly listed side effect.


Q: Does the antiseptic in Orofar kill all germs in the mouth and throat?

The antiseptic component is documented to have broad-spectrum anti-infective and biocide properties. However, its action is focused on localized symptom management and does not eliminate all microbial life in the mouth and throat.


Q: Are the numbing and antiseptic ingredients in Orofar safe for long-term use?

Official regulatory instructions stipulate that Orofar is intended for a short-term course and should typically not be administered for more than five consecutive days.


Q: Can Orofar interfere with taking other oral medications?

Specific drug-drug interactions are documented in the official labeling. The administration procedure requires the lozenge to be dissolved slowly, which helps prevent interference with general oral medication absorption when taken appropriately.


Q: Do children react differently to the active ingredients in Orofar?

Official dosing guidelines provide a reduced maximum daily intake and frequency for children aged 4 to 12 years compared to adults. This difference in recommended usage reflects potential differences in tolerance or pharmacodynamics in the pediatric population.


Q: Can Orofar be used for dry, scratchy throats not related to a cold?

The product is indicated for the symptomatic relief of irritation and pain associated with minor oropharyngeal inflammation, which encompasses symptoms like a dry or scratchy throat.


How should Orofar be stored and disposed of?

Storage and Disposal of Orofar

Storage and disposal requirements for Orofar lozenges are defined in official regulatory documents to ensure product stability and safety. The medicine must be kept at Room Temperature, generally defined as up to 30 C.


Storage Conditions

The lozenges must be protected from environmental factors by storing them in the original container, which must be kept tightly sealed. The storage area should be well-ventilated and protected from direct light, heat, and moisture. A mandatory safety requirement is that the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Orofar must be disposed of via an approved pharmaceutical waste disposal plant. Official guidelines explicitly state that the product should not be allowed to enter drains or be thrown into household waste, as components may require controlled environmental handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Orofar found in:

A-Z Index: